AstraZeneca (LSE: AZN) and development partner Daiichi Sankyo (TYO: 4568) have withdrawn a marketing authorization application for datopotamab deruxtecan (Dato-DXd) in lung cancer.
The firms had submitted for approval to market the antibody-drug conjugate (ADC) for the treatment of a relatively broad population of non-squamous non-small cell lung cancer (NSCLC) patients, but reversed course after feedback from the agency’s scientific panel.
The application was based on results from the Phase III TROPION-Lung01 trial, which showed a progression-free survival benefit for Dato-DXd over chemotherapy in patients with non-squamous NSCLC. However, the study failed to demonstrate a statistically-significant overall survival advantage, a key benchmark for regulatory approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze